News

A single-center study examined whether bevacizumab could continue during treatment with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Among 202 PIPAC procedures in 111 patients, 30-day complications occurred after 5.1% of procedures with bevacizumab and 9.6% without—a difference that was not statistically significant. No deaths, bleeding, perforations, or delayed wound healing occurred. The findings are encouraging, but larger prospective studies are needed before

A U.S. phase I trial evaluated PIPAC with cisplatin and doxorubicin in 15 women with heavily pretreated recurrent ovarian cancer and peritoneal metastases. The procedure was feasible and generally well tolerated, with no dose-limiting toxicities or grade 4–5 events. Some patients showed disease control inside the abdomen, but progression-free survival was limited. Researchers say larger trials should refine patient selection and combination treatments.

For people with malignant peritoneal mesothelioma treated with CRS/HIPEC, prognosis may improve as more time passes after surgery. A two-center study found that the estimated chance of surviving another five years rose among patients who had already survived several years. Lower tumor burden and avoiding serious complications were associated with longer survival. The findings offer hope, but they cannot predict an individual patient’s outcome.

A new study is helping researchers build a clearer genetic map of peritoneal mesothelioma. An analysis of tumor samples from 192 patients identified recurring changes in BAP1, NF2, TP53, and SETD2—genes involved in DNA repair and controlling cell growth. Although the findings do not change current treatment, they highlight biological pathways that could guide future targeted therapies and clinical trials for this rare cancer.

The Abdominal Cancers Alliance is proud to announce that President and Co-Founder Dr. Armando Sardi will participate in the 5th Latin American Congress on Peritoneal Neoplasms—PSOGI LATAM 2026—in Cartagena, Colombia. Dr. Sardi will moderate a session focused on appendiceal tumors and pseudomyxoma peritonei, joining international experts to exchange knowledge, strengthen collaboration, and help advance specialized care for patients with peritoneal cancers.

A Mayo Clinic study found that pancreatic cysts with multiple concerning features may carry a greater risk of progressing to pancreatic cancer or advanced precancerous changes. The three-year risk increased from approximately 2% with one concerning feature to 18% with three or more. The findings may help specialists identify who needs closer monitoring or treatment while allowing patients at lower risk to avoid unnecessary pancreatic surgery.

A small study suggests that early, personalized nutrition support may help patients with pancreatic cancer tolerate more of their prescribed chemotherapy and recover more quickly after surgery. Patients who worked closely with a dietitian had higher chemotherapy completion, shorter hospital stays, and fewer postoperative infections. Although larger studies are needed, the findings support making nutrition an early and ongoing part of pancreatic cancer care.

A study of 101 patients with peritoneal metastases found that long-term survival was possible after cytoreductive surgery, HIPEC, and postoperative intraperitoneal chemotherapy. Five-year overall survival reached 62% for patients with appendix cancer and 34% for those with colorectal cancer. The results highlight the importance of specialized evaluation and removing all visible disease, but the study was small, conducted at one center, and did not include a comparison group.

We're proud to share our 2025 Impact Report, highlighting a year of meaningful growth in awareness, connection, and navigation for patients and caregivers facing advanced abdominal cancers. This report reflects the collective impact of our community working together to help more people access the information and specialized care they need.

For people with advanced ovarian cancer, surgery may take place before chemotherapy or after several cycles of treatment. A recent review found that neither approach is best for everyone. The most important goal is safely removing all visible cancer. Treatment timing should be based on the cancer’s location and extent, the patient’s overall health, and the surgical team’s expertise. Evaluation by an experienced gynecologic oncologist can help guide this complex decision.

Recovering from CRS/HIPEC can bring nutrition challenges that patients and caregivers may not expect. In interviews with 20 colorectal cancer survivors and 10 caregivers, researchers found that diarrhea, early fullness, pain, meal preparation, and changing dietary needs can complicate recovery. The study highlights the value of earlier, ongoing, and individualized nutrition support to help patients and caregivers feel better prepared for life after CRS/HIPEC.

A new study followed 111 patients with pseudomyxoma peritonei (PMP) for one year after cytoreductive surgery (CRS) and HIPEC. Quality of life declined most during the early weeks after surgery, with fatigue, pain, appetite loss, sleep difficulties, and other symptoms affecting recovery. Most measures improved steadily and returned to or approached pre-surgery levels within 6–12 months, offering patients and caregivers valuable insight into what recovery may look like.

A new study found that while CT scans provide a useful estimate of the extent of peritoneal metastases, they often underestimate the amount of cancer found during surgery. Diagnostic laparoscopy may offer a more accurate assessment in selected patients, helping physicians make more informed decisions about cytoreductive surgery.

A new multi-institutional study found that a second cytoreductive surgery (CRS) with or without HIPEC may be a safe option for carefully selected patients with recurrent colorectal cancer that has spread to the peritoneum. Patients who underwent repeat surgery had similar complication rates and lived longer than those treated with systemic therapy or supportive care alone.

A new study examined how often incisional hernias occur after cytoreductive surgery (CRS) and HIPEC for colorectal and appendiceal cancers. Researchers found that patients with a history of prior open abdominal surgery or a previous hernia had the highest risk, highlighting the importance of individualized surgical planning, recovery, and long-term follow-up.

PIPAC is a newer way to deliver chemotherapy directly to cancers that have spread to the lining of the abdomen. Using a minimally invasive procedure, chemotherapy is sprayed as a fine mist to improve drug delivery while reducing side effects. Learn how PIPAC works, who may benefit, how it differs from HIPEC, and why it is being studied in clinical trials.

A new feasibility study found that ultrasound-guided progressive pneumoperitoneum (PPP) allowed patients with "non-accessible" abdomens to safely receive PIPAC, a treatment for peritoneal carcinomatosis. While only five patients were studied, all successfully underwent PIPAC without major complications, suggesting this technique may expand treatment options for selected patients.

If your care team recommends chemotherapy before stomach cancer surgery, you may wonder whether it makes surgery riskier. This study found that patients who received chemotherapy before surgery had similar complication rates, hospital stays, and survival as those who had surgery first—and were even less likely to be readmitted to the hospital after surgery.

HIPEC has moved from controversy toward becoming an important treatment option for carefully selected patients with advanced ovarian cancer. This editorial reviews the growing evidence showing improved survival without added long-term quality-of-life concerns and highlights why treatment at experienced CRS/HIPEC centers is so important.